Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
We expect to conduct a clinical trial in recurrent and metastatic nasopharyngeal carcinoma patients to explore and compare the efficacy and safety of induction chemotherapy (TPC vs. GP) with combination therapy of Camrelizumab.
Epistemonikos ID: dddab8ae81bc687d9c3d221d7d599cf85a0541bd
First added on: Dec 01, 2024